RNA Therapeutics
RNA- The Language of Future Therapies
Why RNA Therapeutics Database ?
Dive deeper into ARN therapeutics drug and clinical trial data with a very powerful search filters. Easily segment the ARN therapeutics landscape and pinpoint the insights that matter most. Our filters include:
Determine whether your ARN therapy can achieve first-in-class or best-in-class status with powerful search capabilities exploring delivery platforms, target organs and cells, and nucleic acid modifications used by other developers allowing you to measure your drug’s uniqueness and define its competitive market position.
Run delivery-focused RNA queries through advanced search tools designed to explore proprietary technologies. Our platform indexes hundreds of delivery systems, carefully categorized across conjugates, nanoparticles, peptides, antibodies, and other emerging delivery approaches.
Quickly explore innovative strategies and the supporting data behind targeted RNA delivery using additional search parameters such as:
Target organ or cell type
Route of administration
Nucleic acid modifications
Genetic material used for therapy
Once relevant delivery technologies are identified across the RNA therapeutics landscape, dive deeper into comprehensive, manually curated datasets covering both preclinical and clinical DMPK information. This enables researchers to evaluate successful extra-hepatic delivery strategies, benchmark leading approaches, and refine their own RNA delivery platforms.
As an increasing number of RNA therapeutics programs enter development pipelines, accessing comprehensive data on emerging therapies and understanding which experiments enabled successful transition into clinical trials has become increasingly complex.
Our platform provides extensive access to curated preclinical RNA data, allowing you to explore publicly available experimental results across key research areas, including:
In vitro assays
Therapeutic efficacy
Pharmacokinetics (PK)
Toxicity studies
Animal models and cell lines
Advanced filtering tools enable rapid identification of RNA programs that have released preclinical datasets. Researchers can then review expert-curated summaries compiled from scientific journals, conference presentations, corporate reports, and numerous other sources offering a clear and reliable overview to guide the design and optimization of your own preclinical RNA development strategy.
Explore clinical trials using advanced search tools that combine RNA technology parameters—such as therapeutic class, delivery systems, target organs or cells, and editing technologies—with key clinical trial criteria including phase, trial status, geographic location, and therapeutic indication. This allows you to quickly identify relevant global RNA trials to benchmark, replicate, or improve upon.
After identifying trials aligned with your clinical development strategy, access detailed manually curated data on trial design and outcomes, including:
Drug dosing strategies
Patient population data
Toxicity and safety readouts
Clinical endpoints and outcomes
Our platform continuously updates clinical datasets as new information becomes available, ensuring researchers and developers have reliable, up-to-date insights to confidently design and optimize RNA clinical trials.
How RNA Tharapeutics Can Help You?
Let's Discover What is The RNA Tharapy
Small Molecules, Big Medical Breakthroughs
RNA and gene therapies represent an interdisciplinary field that combines molecular biology, genetics, biotechnology, pharmacology, pharmaceutics, and clinical medicine. These innovative approaches aim to transform healthcare by developing treatments that directly target the molecular causes of disease.
Such therapies offer several key advantages:
Personalized : designed according to the molecular profile of an individual, including genetic (DNA) or transcriptomic (RNA) information.
Precise : focused on the underlying molecular mechanisms of disease, such as specific genetic mutations or pathological pathways, while minimizing disruption to normal physiological functions.
Flexible : capable of adapting to evolving disease patterns, including viral mutations or therapy-resistant tumors.
Variable in duration : therapeutic effects can range from short-term responses, such as antigen production from mRNA vaccines, to long-lasting or even permanent outcomes through DNA modification.
How Does Gene Therapy Work?
Gene therapy works by modifying a person’s genetic information to restore or improve the function of essential proteins. Proteins play a fundamental role in the body—they perform most cellular tasks and form the structural foundation of tissues and organs. The instructions for producing these proteins are encoded in DNA. When mutations occur in this genetic code, they may disrupt the production or activity of important proteins, leading to disease.
Gene therapy aims to correct or compensate for these genetic alterations so that normal cellular function can be restored.
Main Approaches in Gene Therapy
Gene Addition
Gene addition is a type of gene therapy that targets a specific gene in the body’s cells. This approach adds a working copy of a gene into the cell or adds another gene to bypass the problem. The added gene allows the body to make proteins to potentially manage or treat a genetic disease.
Gene Silencing
Patient stem cells are collected and transported to a laboratory where they are genetically modified.
During this process, the gene responsible for producing the BCL11A protein, which normally suppresses the production of hemoglobin F, is silenced. When this gene is turned off, the production of hemoglobin F can be reactivated.
As a result, the patient’s cells begin producing hemoglobin F, a non-sickling form of hemoglobin, which helps prevent the abnormal shaping of red blood cells associated with sickle cell disease.
Gene Correction
Patient-derived stem cells are extracted and transported to a laboratory for genetic modification.
The harmful gene variant responsible for sickle cell disease is precisely corrected, enabling the production of healthy, non-sickling hemoglobin.
